Mangoceuticals, Inc. — Form 8-K Summary
Event date: September 30, 2026. The report was signed and filed October 1, 2026. This is a material transaction disclosure, not a periodic financial-results filing.
Business context and transaction
MangoRx IP Holdings, LLC, a wholly owned subsidiary that holds the patent portfolio behind the company’s MGX-0024 antiviral technology, entered into subscription agreements with two accredited investors to sell membership interests.
- The agreements provide for aggregate investment of $2.5 million for a 25% interest in MangoRx IP: each investor agreed to invest $1.25 million for 12.5%.
- One investor’s $1.25 million is payable in two installments: $500,000 at signing and $750,000 no later than 60 days after the initial closing. The other investor’s $1.25 million was payable at the initial closing.
- As of the filing, the company reported receiving $1.75 million and issuing interests described as 18.9% of ownership interests, or 17.5% on a post-transaction basis. The interest is expected to increase to 25% upon the final closing.
Financial metrics and changes
The filing does not report revenue, profit, cash flow, margins, debt, or broader liquidity metrics. It reports $1.75 million received to date from the private placement, with a further $750,000 installment due under one agreement. No pro forma information was provided; the company stated that MangoRx IP is not a “business” for purposes of the cited reporting requirement.
The transaction brings in capital while transferring a minority ownership interest in the subsidiary holding the MGX-0024 patent portfolio. The filing provides no comparable-period operating results.
Outlook, risks, and other matters
- The remaining $750,000 payment and final closing are not yet complete as of the filing. The stated 25% interest depends on that final closing.
- The membership interests were issued in an unregistered offering to accredited investors, with the company claiming exemptions under Securities Act Section 4(a)(2) and/or Regulation D Rule 506. The interests carry transfer restrictions.
- The filing includes customary forward-looking-statement cautions and notes that actual outcomes may differ due to risks and uncertainties. It does not provide operating guidance or a detailed outlook for MGX-0024.
Important facts for investors to verify
- Whether the outstanding $750,000 installment was paid and the final closing occurred.
- The exact ownership percentages issued and retained, including the filing’s distinction between 18.9% of ownership interests and 17.5% on a post-transaction basis.
- The full subscription agreement terms and any effects of the transaction on the company’s control, economics, or rights in MangoRx IP.
- Subsequent disclosures on MGX-0024 development, commercialization, and associated costs or risks.